Will the first-line induction therapy of bortezomib for newly diagnosed multiple myeloma be challenged in the era of novel drugs? / 白血病·淋巴瘤

ABSTRACT

For newly diagnosed multiple myeloma (MM) patients, bortizomib based on chemotherapy has achieved desirable complete remission rate, good progression-free survival and overall survival, which is now a first-line choice in both transplant-eligible and transplant-ineligible patients. In recent years, other new treatment options such as proteasome inhibitors , immunomodulators , monoclonal antibody and cellular immunotherapy have posed a challenge to the first-line therapeutic status of bortizomib because of their favorable efficacy and safety. Oral proteasome inhibitor or monoclonal antibody combined with immunomodulators and dexamethasone might become the first-line induction therapy of newly-diagnosed MM patients. Moreover, chimeric antigen receptor T-cell immunotherapy (CAR-T) may also play a role in the first-line treatment, especially for the induction therapy of high-risk patients and the consolidation treatment of the elimination in minimal residual disease.